ArticleAnnals of hematology2025

PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.

Abdulraheem Yacoub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.